4HF Biotec
Private Company
Funding information not available
Overview
4HF Biotec is a private, preclinical-stage biotech leveraging a unique AI-driven in silico platform, the 4HF CancerDataMiner™, to discover and develop novel small molecule drug conjugates (SMDCs) for oncology. The company operates a hybrid business model, advancing its own pipeline while offering in silico research services to industry partners. Its lead project, SELECTHERA, is a collaboration with the German Cancer Research Center (DKFZ/DKTK) focused on developing tumor-selective toxins and radioligands for prostate and lung cancer.
Technology Platform
4HF CancerDataMiner™ - a proprietary in silico platform that synergizes multi-omics cancer data, computational sciences, and AI-driven drug discovery to identify novel cancer-specific targets and associated small molecule effectors.
Opportunities
Risk Factors
Competitive Landscape
4HF competes in the targeted oncology space, primarily against developers of Antibody-Drug Conjugates (ADCs) and other biotechs exploring Small Molecule Drug Conjugates (SMDCs). Its differentiation lies in its AI/omics-driven discovery platform and its specific focus on novel SMDCs for solid tumors.